1:45 PM
 | 
Sep 27, 2018
 |  BC Innovations  |  Translation in Brief

Twice as splice

Why Abivax is developing its anti-HIV therapy for inflammatory diseases

Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and ulcerative colitis.

According to CEO Hartmut Ehrlich, ABX464 binds the human cap binding complex (CBC) and promotes its splicing activity. The company already knew the compound prevents HIV from entering patients’ blood by accelerating the splicing of an mRNA the virus needs...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >